Fitxa persona

ANA BLAS GARCIA
PDI-Prof. Permanent Laboral Ppl

Knowledge area: PHYSIOLOGY
Department: Physiology

(9635) 44893

Subjects taught and teaching methods

33962 - Pathophysiology - Degree in Human Nutrition and Dietetics	Seminars, Theory, Tutoring
33971 - Degree Final Project in Human Nutrition and Dietary - Degree in Human Nutrition and Dietetics	Work end of studies
34085 - Physiopathology - Degree in Pharmacy	Seminars, Theory, Tutoring
34085 - Physiopathology - Double Degree in Pharmacy and Human Nutrition and Dietetics	Seminars, Theory, Tutoring
34090 - Clinical Biochemistry and Hematology - Degree in Pharmacy	Seminars, Theory, Tutoring
34092 - Degree Final Project in Pharmacy - Degree in Pharmacy	Work end of studies
34452 - Medical physiology III - Degree in Medicine	Laboratory
36313 - Final project in Pharmacy - Human Nutrition and Dietetics - Double Degree in Pharmacy and Human Nutrition and Dietetics	Work end of studies

Tutorials

First semester

Monday de 09:00 a 12:00. DESPACHO 2.16-DPTO. FISIOLOGIA-F.FARMACIA

Second semester

Monday de 11:00 a 14:00. DPTO. FISIOLOGIA-F. MEDICINA

Observations

You participate in the electronic tutoring program of the Universitat de València

Journal Publications

Activity interests

Participations in Conferences

Alberto Martí-Rodrigo; Ángela B. Moragrega; Aleksandra Gruevska; Anabel Fernández-Iglesias; Jordi Gracia-Sancho; Juan V. Esplugues; Nadezda Apostolova; Ana Blas-García. 2019. Selective activation of STAT1-dependent apoptosis in hepatic stellate cells by rilpivirine as a new therapeutic option for liver fibrosis. . UEG (United European Gastroenterology) Week 2019 Barcelona. SPAIN.
Martí-Rodrigo A; Moragrega ÁB; Gruevska A; Fernández-Iglesias A; Gracia-Sancho J, Esplugues JV, Apostolova N, Blas-Garcia A. 2019. Selective activation of Jak-Stat1-mediated apoptosis in hepatic stellate cells as a new therapeutic option for liver fibrosis: role of rilpivirine. . The International Liver congress - 54th Annual Meeting of the European Association for the Study of the Liver Viena. AUSTRIA.
Federico Lucantoni, Aleksandra Gruevska, Ángela B. Moragrega, Juan V. Esplugues, Ana Blas-García and Nadezda Apostolova. 2020. The antiretroviral drug Rilpivirine alters autophagy in both quiescent and activated human stellate cells: novel targets for treatment of liver fibrosis. . II Congreso de Sefagia (Sociedad Española de Estudio de la Autofagia) Cáceres. SPAIN.
Maria Luisa Montes; Carmen Busca; Angela B. Moragrega; Nadezda Apostolova; Antonio Olveira; Luz Martin Carbonero; Eulalia Valencia; Victoria Moreno; Jose I. Bernardino; Ignacio Perez-Valero; Juan González-García; Juan V. Espluges; Jose R. Arribas; Ana Blas-García. 2021. RPV activates STAT1 in stellate cells to regulate liver injury in PLWHIV and NAFLD. . Conference on Retroviruses and Opportunistic Infections (CROI) Virtual. UNITED STATES.
Federico Lucantoni; David-Verdú Coloma; Alberto Martí-Rodrigo; Aleksandra Gruevska; Ángela B. Moragrega; Jordi Gracia-Sancho; Juan V. Esplugues; Nadezda Apostolova; Ana Blas-García. 2021. Rilpivirine and simvastatin exert a synergistic antifibrogenic effect in vitro on hepatic stellate cells through oxidative stress regulation. . International Workshop on Liver and Gut Fibrosis Valencia. SPAIN.
Isabel Fuster-Martínez; José F. Català-Senent; Francisco J. Roig; Juan V. Esplugues; Nadezda Apostolova; Francisco García-García; Ana Blas-García. 2021. Transcriptomic signature of high fat diet murine models of NAFLD and its modulation by anti-steatotic treatments: a meta-analysis. . Digital NAFLD Summit 2021 Formato virtual. SWITZERLAND.
Ana Blas-García. 2019. Identificación de nuevas dianas farmacológicas para la fibrosis hepática: regulación de las rutas de señalización Jak-STAT1 y Jak-STAT3. . XIII Jornadas Científicas CIBERehd SPAIN.
A. Martí-Rodrigo, Ángela B. Moragrega, P. Martí-Rodrigo, D. Castelli, N. Apostolova, Juan V. Esplugues, A. Blas-García. 2018. The antiretroviral rilpivirine induces hepatic regeneration in liver fibrosis and cirrhosis by modulating the STAT3/STAT1 balance. . The International Liver Congress 2018. 53rd annual meeting of the European Association for the Study of the Liver Paris. FRANCE.
A. Martí Rodrigo, A.B. Moragrega, P. Martí Rodrigo, D. Castelli, N. Apostolova, J.V. Esplugues, A. Blas-García. 2018. El antirretroviral Rilpivirina favorece la regeneración hepática en modelos in vivo de fibrosis y cirrosis a través de la activación de STAT3. . 43º Congreso Anual de la Asociación Española para el Estudio del Hígado Madrid. SPAIN.
Federico Lucantoni; Aleksandra Gruevska; Ángela B. Moragrega; Alberto Martí-Rodrigo; Juan V. Esplugues; Ana Blas-García; Nadezda Apostolova. 2021. The hepatoprotective role of the antiretroviral drug Rilpivirine is associated with altered autophagy in in vitro and in vivo models of liver fibrosis. . International Liver Congress 2021 Virtual. SWITZERLAND.
Ángela B. Moragrega; Aleksandra Gruevska; Isabel Fuster-Martínez; Ana M. Benedicto; Federico Lucantoni; Juan V. Esplugues; Nadezda Apostolova; Ana Blas-García. 2021. Inhibition of CCL2/CCR2 signaling promotes rilpivirine-induced anti-fibrotic and anti-inflammatory effects in liver diseases. . International Workshop on Liver and Gut Fibrosis Valencia. SPAIN.
Isabel Fuster-Martínez; José F. Catalá-Senent; Francisco J. Roig; Juan V. Esplugues; Nadezda Apostolova; Francisco García-García; Ana Blas-García. 2021. Transcriptomic signature of high fat diet murine models of NAFLD reveals a core set of liver fibrosis-promoting genes reversed by anti-steatotic treatments. . International Workshop on Liver and Gut Fibrosis Valencia. SPAIN.
Ana M. Benedicto, Aleksandra Gruevska, Isabel Fuster-Martínez, Ángela B. Moragrega, Federico Lucantoni, Juan V. Esplugues, Ana Blas-García and Nadezda Apostolova. 2021. Molecular evidence of potential rilpivirine-induced regenerative effects in mouse models of liver injury. . International Workshop on Liver and Gut Fibrosis Valencia. SPAIN.
Ana Blas-García. 2020. Ejemplo práctico real: reposicionamiento de fármacos para el tratamiento de la fibrosis hepática. . Jornadas de Hepatología Traslacional Online: Actualización en el estudio de las enfermedades hepáticas SPAIN.
Aleksandra Gruevska; Ángela B. Moragrega; Federico Lucantoni; Joan Tosca; Cristina Montón; Juan V Esplugues; Ana Blas-Garcia; Nadezda Apostolova. 2021. IP-10/CXCL10: a potential target of the antiretroviral drug rilpivirine in liver fibrosis attenuation. . 3ª Reunión de Hepatología Traslacional Alicante. SPAIN.
Ana Blas-García. 2021. Fibrosis regression: the example of the antiretroviral rilpivirine. . International Workshop on Liver and Gut Fibrosis SPAIN.
Ana Blas-García. 2021. Comunicación intercelular de células estrelladas hepáticas en la progresión y regresión de la fibrosis. . I Jornadas Complutenses sobre Enfermedades Metabólicas SPAIN.
Blas-García A, Alegre F, Polo M, Ortiz-Masià D, Funes HA, Martí-Rodrigo A, Apostolova N. 2014. The non-nucleoside Reverse Transcriptase Inhibitor Efavirenz induces an inflammatory response in hepatic cells controlled by autophagy. . The Liver Meeting 2014 AASLD - 65th Annual Meeting of the American Association for the Study of Liver Diseases Boston . UNITED STATES.
Alegre F; Polo M; Martí-Rodrigo A; Moragrega A; Esplugues JV; Blas-García A; Apostolova N. 2017. p62/SQSTM1 in a drug-induced model of hepatotoxicity: a novel role beyond autophagy. . International Liver Congress Amsterdam . NETHERLANDS.
Blas-García A, Martí-Rodrigo A, Polo M, Alegre F, Funes HA, Apostolova N, Esplugues JV. 2014. Acute inhibition of electron transport chain complexes by Abacavir and Didanosine predisposes hepatic cells to mitocondria-dependnent liver injury. . 16th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV Filadelfia. UNITED STATES.
Ángela B. Moragrega; Alberto Martí-Rodrigo; Aleksandra Gruevska; Juan V. Esplugues; Nadezda Apostolova; Ana Blas-García. 2019. Rilpivirine-induced anti-inflammatory effects in liver diseases involve the activation of STAT6 signaling pathways in macrophages. . UEG (United European Gastroenterology) Week 2019 Barcelona. SPAIN.
Martí-Rodrigo A; Alegre F; Polo M; Moragrega A; Apostolova N; Esplugues JV; Blas-García A. 2017. The anti-HIV drug rilpivirine decreases hepatic injury in a nutritional model of NAFLD through activation of the IL6/IL22-STAT3-p53 axis. . International Liver Congress Amsterdam . NETHERLANDS.
Martí-Rodrigo A; Alegre F; Moragrega AB; Polo M; Apostolova N; Esplugues JV; Blas-García A. 2017. The antiretroviral rilpivirine decreases hepatic inflammation and fibrosis progression in different experimental mice models of fibrosis. . The Liver Meeting 2017 (American Association for the Study of Liver Diseases) Washington . UNITED STATES.
Martí-Rodrigo A; Alegre F; Polo M; Apostolova N; Esplugues JV; Blas-García A. 2016. Chronic administration of the non-nucleoside reverse transcriptase inhibitors efavirenz and rilpivirine decreases hepatic steatosis and fibrogenic response in a mouse model of NAFLD. . EASL Monothematic Conference: "Liver fibrosis: the next goal on targeted therapy?" Oporto. PORTUGAL.
Alegre F; Polo M; Marti-Rodrigo A; Apostolova N; Esplugues JV; Blas-García A. 2015. Efavirenz alters the expression of inflammatory and fibrinogenic markers in hepatic stellate cells and liver tissue. . 17th International Workshop on Co-Morbidities and Adverse Drug Reactions in HIV Barcelona. SPAIN.
Ángela B. Moragrega; Alberto Martí-Rodrigo; Aleksandra Gruevska; Juan V. Esplugues; Nadezda Apostolova; Ana Blas-García. 2019. Efecto anti-inflamatorio del antirretroviral Rilpivirina en la enfermedad hepática crónica. . 44º Congreso de la Asociación Española para el Estudio del Hígado (AEEH) Madrid. SPAIN.
Alberto Martí-Rodrigo; Ángela B. Moragrega; Aleksandra Gruevska; Juan V. Esplugues; Nadezda Apostolova; Ana Blas-García. 2019. Rilpivirina reduce el daño hepático inducido por colestasis a través de la inactivación de células estrelladas hepáticas. . 1ª Reunión de Hepatología Traslacional: Status Quo y nuevos horizontes en el estudio del hígado San Sebastián. SPAIN.
Ana Blas-García, Alberto Martí-Rodrigo, Ángela B. Moragrega, Aleksandra Gruevska, Nadezda Apostolova, Juan V. Esplugues. 2018. Rilpivirina como fármaco hepatoprotector en la progresión de la enfermedad hepática crónica. . XII Jornadas Científicas CIBERehd Barcelona. SPAIN.
A. Blas-García, A. Martí Rodrigo, Á.B. Moragrega, P. Martí Rodrigo, D. Castelli, N. Apostolova, J.V. Esplugues Mota. 2018. El antirretroviral Rilpivirina reduce el daño hepático en un modelo nutricional de EHGNA a través de la resincronización del reloj circadiano hepático. . 43º Congreso Anual de la Asociación Española para el Estudio del Hígado Madrid. SPAIN.
Martí-Rodrigo A; Alegre F; Miriam Polo; Moragrega A; Apostolova N; Esplugues JV; Blas-García A. 2017. El antiretroviral rilpivirina reduce el daño hepático en un modelo nutricional de HGNA a través de la activación del eje IL6/IL22-STAT3-P53 en células estrelladas. PREMIO AL MEJOR POSTER. . 42 Congreso Anual de la Asociación Española para el Estudio del Hígado Madrid. SPAIN.
Alegre F; Martí-Rodrigo A; Miriam Polo; Moragrega A; Ortiz-Masia D; Pinti M; Apostolova N; Esplugues JV; Blas-García A. 2017. Los macrófagos hepáticos modulan el daño hepático agudo inducido por la activación del inflamasoma NLRP3: el ejemplo de Efavirenz. . 42 Congreso Anual de la Asociación Española para el Estudio del Hígado Madrid. SPAIN.
Alegre F; Moragrega AB; Martí-Rodrigo A; Esplugues JV; Blas-García A, Apostolova N. 2017. P62 upregulation mediated through CHOP/DDIT3 is protective in a cell model of drug-induced hepatoxicity. . Second NEAR Meeting (Network of Excellence for Autophagy Research) Miraflores de la Sierra . SPAIN.
Polo M; Moragrega AB, Alegre F; Martí-Rodrigo A; Blas-García A; Esplugues JV; Apostolova N. 2016. Novel function of mitochondrial Lon protease (LONP) in an Efavirenz-induced dual model of ER-stress and mitochondrial dysfunction in hepatic cells. . VIII Congreso Nacional de GESIDA San Sebastian. SPAIN.
David Verdú-Coloma, Federico Lucantoni, Alberto Martí-Rodrigo, Aleksandra Gruevska, Ángela B. Moragrega, Jordi Gracia-Sancho, Juan V. Esplugues, Ana Blas-García and Nadezda Apostolova. 2020. A synergistic effect between Rilpivirine and Simvastatin in the context of liver fibrogenesis in vitro. . 45 Congreso Anual de la Asociación Española para el Estudio del Hígado (AEEH) Madrid. SPAIN.
Angela B. Moragrega; Aleksandra Gruevska; Isabel Fuster-Martínez; Ana Benedicto; Federico Lucantoni; Juan V. Esplugues; Nadezda Apostolova; Ana Blas-García. 2021. Rilpivirine-induced anti-inflammatory effects in non-alcoholic fatty liver disease involve the inhibition of CCL2/CCR2 axis. . International Liver Congress 2021 Virtual. SWITZERLAND.

Projects